Dataset Information

Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant.

ABSTRACT: (1) Background: SARS-CoV-2 infections are associated with an increased risk of hospital admissions especially in the elderly (age ≥ 65 years) and people with multiple comorbid conditions. (2) Methods: We investigated the effect of additional booster vaccinations following the primary vaccination series of mRNA, inactivated whole virus, or vector vaccines on infections with the SARS-CoV-2 delta variant in the total Hungarian elderly population. The infection, hospital admission, and 28-day all-cause mortality of elderly population was assessed. (3) Results: A total of 1,984,176 people fulfilled the criteria of elderly including 299,216 unvaccinated individuals, while 1,037,069 had completed primary vaccination and 587,150 had obtained an additional booster. The primary vaccination series reduced the risk of infection by 48.88%, the risk of hospital admission by 71.55%, and mortality by 79.87%. The booster vaccination had an additional benefit, as the risk of infection, hospital admission, and all-cause mortality were even lower (82.95%; 92.71%; and 94.24%, respectively). Vaccinated patients needing hospitalization suffered significantly more comorbid conditions, indicating a more vulnerable population. (4) Conclusions: Our data confirmed that the primary vaccination series and especially the booster vaccination significantly reduced the risk of the SARS-CoV-2 delta-variant-associated hospital admission and 28-day all-cause mortality in the elderly despite significantly more severe comorbid conditions.

SUBMITTER: Muller V

PROVIDER: S-EPMC9321254 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant.

Müller Veronika V Polivka Lorinc L Valyi-Nagy Istvan I Nagy Alexandra A Szekanecz Zoltan Z Bogos Krisztina K Vago Hajnalka H Kamondi Anita A Fekete Ferenc F Szlavik Janos J Elek Jeno J Surján György G Surján Orsolya O Nagy Péter P Schaff Zsuzsa Z Müller Cecília C Kiss Zoltan Z Kásler Miklós M

Vaccines 20220621 7

(1) Background: SARS-CoV-2 infections are associated with an increased risk of hospital admissions especially in the elderly (age ≥ 65 years) and people with multiple comorbid conditions. (2) Methods: We investigated the effect of additional booster vaccinations following the primary vaccination series of mRNA, inactivated whole virus, or vector vaccines on infections with the SARS-CoV-2 delta variant in the total Hungarian elderly population. The infection, hospital admission, and 28-day all-ca ...[more]

PMID: 35891151

Similar Datasets

Project description:BackgroundIntracerebral hemorrhage (ICH) is associated with high mortality and morbidity rates. Although some studies have indicated a correlation between serum bilirubin levels and ICH severity, evidence of the relationship between serum total bilirubin (TBIL) and ICH outcomes remains lacking.MethodsA total of 914 patients from the Medical Information Mart for Intensive Care IV database met the eligibility criteria and were included in the study. The patients were categorized into two groups based on whether they survived for 28 days following admission to hospital. The association between serum TBIL levels and 28-day survival in patients with ICH was investigated using Spearman's correlation analysis and restricted cubic splines. The effect of serum TBIL levels on survival time and rate in the 28-day period was analyzed using Kaplan-Meier curves and restricted mean survival times. Univariate Cox regression, least absolute shrinkage and selection operator regression, and multivariate Cox regression were used to identify risk factors associated with 28-day all-cause mortality. Finally, subgroup analysis was performed to verify the stability of the association between serum TBIL levels and 28-day all-cause mortality in patients with ICH.ResultsA negative relationship was revealed between TBIL levels and survival (p < 0.001, correlation = -0.174). Restricted cubic spline analysis revealed a nonlinear link between mean serum TBIL levels and 28-day all-cause mortality (p for nonlinear = 0.001). Patients with ICH and higher serum TBIL levels had significantly reduced survival times and rates compared with those with lower serum TBIL levels (p < 0.001). Serum TBIL level was identified as a significant risk factor for 28-day all-cause mortality in patients with ICH (hazard ratio [95% confidence interval] = 1.121 [1.063-1.182], p < 0.001). Subgroup analyses revealed that the assessed variables had no influence on the association between serum TBIL levels and 28-day all-cause mortality.ConclusionHigher serum TBIL levels are associated with a greater risk of mortality within 28 days in patients with ICH, whereas lower serum TBIL levels are associated with prolonged survival.

Dataset Information

Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant.

Publications

Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets